The effects of albumin-bound paclitaxel combined with cisplatin injections on patients with advanced laryngeal cancer and serum survivin.

Objective To explore the effects of the TP (Taxol plus Platinol) regimen and the PF (Platinol plus fluorouracil) regimen on patients with advanced laryngeal cancer and on the patients' VEGF-C (vascular endothelial growth factor C) and survivin genes. Methods 42 patients with locally advanced laryngeal cancer treated in our hospital from June 2018 to October 2020 were recruited as the study cohort. The patients were assigned into a control group (21 cases) or an observation group (21 cases). The control group was administered the PF regimen, and the observation group was administered the TP regimen. Both groups were treated for four consecutive courses. The clinical efficacy of the two groups of patients was observed, and the two groups' treatment effects, their serum VEGF-C, and survivin levels, and their adverse reactions were compared. Results A superior clinical efficacy was observed in the observation group (85.7%) than in the control group (57.1%) (P 0.05). After the treatment, apparently lower serum VEGF-C and survivin levels in the observation group were measured, and both groups witnessed a decline in their levels (P 0.05). Conclusion The TP regimen in the treatment of laryngeal cancer can reduce the VEGF-C and survivin levels in patients and has a better therapeutic effect, so it is worthy of clinical promotion.